Patient risk stratification algorithm for the treatment of cancer-associated thrombosis. Currently, edoxaban and rivaroxaban are the only direct-acting oral anticoagulants (DOACs) with randomized controlled trial evidence in cancer-associated thrombosis, with the evidence base being stronger for edoxaban. Refer to the relevant product monograph for appropriate dosing. DVT = deep vein thrombosis; PE = pulmonary embolism; GI = gastrointestinal; GFR = glomerular filtration rate; DOAC = direct-acting oral anticoagulant; LMWH = low molecular weight heparin; BMI = body mass index; VTE = venous thromboembolism. #DOAC #VTE #Malignancy #Cancer #Algorithm #Anticoagulation #Management #Hematology #Oncology
